IPX-750

IPX-750 is a **small molecule pro-drug** designed to improve the neural bioavailability of dopamine by conjugating it with gluconamine. This modification enables IPX-750 to utilize glucose transporters (GLUT1, GLUT3, and SGLT1) for crossing the blood-brain barrier, as well as the dopamine transporter (DAT)[1][3][5]. Once inside the CNS, tissue amidases cleave IPX-750 to release active dopamine. IPX-750 acts as a **stereoselective agonist at dopamine D1 and D5 receptors**, with lower activity at D2 receptor, and increases intracellular cAMP. It is developed specifically for **Parkinson’s disease** and has demonstrated efficacy in three animal models, notably improving motor performance and exerting anti-parkinsonian effects without observed neurotoxicity in vitro at pharmacologically active concentrations[1][3][5]. IPX-750 is bioavailable following both oral administration and injection; it accumulates in brain and liver tissues and exhibits sustained effects after treatment cessation[3].

Brand names

IPX-750IPX750IPX 750

Other names

dopamine gluconamine